Chinese hamster ovary (CHO) cells are the preferred mammalian host for the large-scale
production of recombinant proteins in the biopharmaceutical industry. Research endeavors …

As the era of omics continues to expand with increasing ubiquity and success in both
academia and industry, omics-based experiments are becoming commonplace in industrial …

Gene therapy is poised to transition from niche to mainstream medicine, with recombinant
adeno-associated virus (rAAV) as the vector of choice. However, robust, scalable …

The secretory capacity of Chinese hamster ovary (CHO) cells remains a fundamental
bottleneck in the manufacturing of protein-based therapeutics. Unconventional biological …

With the upgrade and development of the high-throughput sequencing technology, multi-
omics data can be obtained at a low cost. However, mapping tools that existed for microbial …

Chinese hamster ovary (CHO) cells are the cell line of choice for producing recombinant
therapeutic proteins. Despite improvements in production processes, reducing …

The demand of biotherapeutics produced by mammalian cells, especially monoclonal
antibodies (mAb) expressed by Chinese Hamster Ovary (CHO) cells, increased significantly …

Omics technologies including genomics, proteomics, metabolomics, and lipidomics allow
profound insights into health and disease. Thanks to plummeting costs of continuously …

Process intensification is increasingly used in the mammalian biomanufacturing industry.
The key driver of this trend is the need for more efficient and flexible production strategies to …

Biotherapeutics, particularly monoclonal antibodies (mAbs) and recombinant adeno-
associated viruses (rAAVs), have transformed the treatment landscape for various diseases …